Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Dana-Farber Cancer Institute

InstitutionResearch output, impact & collaborations

Dana-Farber Cancer Institute is a research organisation in Boston, US. OpenAlex records 89,208 works and 27,485,770 citations for it. 14,518 researchers list it as their most recent affiliation.

89,208
Works
27,485,770
Citations
14,518
Researchers
70.7
Avg h-index

How has Dana-Farber Cancer Institute's publication output changed over time?

ScholarIQpublication output · 2004–2017

Output declined50% over the shown period — from 2 works in 2004 to 1 in 2017.

2
1
1
2
1
2
1
1
1
200420052006200720092010201120162017

Who are the most-cited researchers behind Dana-Farber Cancer Institute?

ScholarIQtop researchers by citations
1
Henry W. Long · Epigenetics and DNA Methylation
650 works12,942 citations
2
Biagio Ricciuti · Lung Cancer Treatments and Mutations
1,111 works11,209 citations
3
Christine E. Ryan · Chronic Lymphocytic Leukemia Research
194 works7,847 citations
4
Francesco Facchinetti · Fibroblast Growth Factor Research
319 works4,030 citations
5
Nora Feeney · Cancer Genomics and Diagnostics
42 works2,373 citations

What are the most-cited papers on Dana-Farber Cancer Institute?

ScholarIQmost cited works
Bioconductor: open software development for computational biology and bioinformatics
Robert Gentleman, Vincent J. Carey, Douglas M. Bates, Ben Bolstad, Marcel Dettling, Sandrine Dudoit, Byron Ellis, Laurent Gautier, Yongchao Ge, Jeff Gentry, Kurt Hornik, Torsten Hothorn, Wolfgang Huber, Stefano M. Iacus, Rafael A. Irizarry, Friedrich Leisch, Cheng Li, Martin Maechler, Anthony Rossini, Günther Sawitzki, Colin A. Smith, Gordon K. Smyth, Luke Tierney, Jean Yang, Jianhua Zhang
S81160022. 200412,580 CitationsOPEN ACCESS
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal I. Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, Matthew Meyerson
Science. 20049,435 Citations
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry, Julie R. Brahmer, Joan H. Schiller, Afshin Dowlati, Rogério Lilenbaum, David H. Johnson
New England Journal of Medicine. 20065,784 CitationsOPEN ACCESS
A Draft Sequence of the Neandertal Genome
Richard E. Green, Johannes Krause, Adrian W. Briggs, Tomislav Maričić, Udo Stenzel, Martin Kircher, Nick Patterson, Heng Li, Weiwei Zhai, Markus Hsi-Yang Fritz, Nancy F. Hansen, Éric Durand, Anna‐Sapfo Malaspinas, Jeffrey D. Jensen, Tomàs Marquès‐Bonet, Can Alkan, Kay Prüfer, Matthias Meyer, Hernán A. Burbano, Jeffrey M. Good, Rigo Schultz, Ayinuer Aximu‐Petri, Anne Butthof, Barbara Höber, Barbara Höffner, Madlen Siegemund, Antje Weihmann, Chad Nusbaum, Eric S. Lander, Carsten Russ, Nathaniel Novod, Jason P. Affourtit, Michael Egholm, Christine Verna, Pavao Rudan, Dejana Brajković, Željko Kućan, Ivan Gušić, Vladimir B. Doronichev, Liubov V. Golovanova, Carles Lalueza‐Fox, Marco de la Rasilla Vives, Javier Fortea, Antonio Rosas, Ralf W. Schmitz, Philip L. Johnson, Evan E. Eichler, Daniel Falush, Ewan Birney, James C. Mullikin, Montgomery Slatkin, Rasmus Nielsen, Janet Kelso, Michael Lachmann, David Reich, Svante Pääbo
Science. 20104,592 CitationsOPEN ACCESS
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne
Science. 20074,477 CitationsOPEN ACCESS

Who collaborates most closely around Dana-Farber Cancer Institute?

ScholarIQco-authorship network
United States
100%

How much of the research on Dana-Farber Cancer Institute is open access?

ScholarIQopen access share
75%OPEN ACCESS
Gold
8%
Green
17%
Hybrid
0%
Bronze
50%
Closed
25%

Related on ScholarIQ

Cancer Genomics and Diagnostics
Top Topic
Cancer Immunotherapy and Biomarkers
Top Topic
Multiple Myeloma Research and Treatments
Top Topic
Chronic Lymphocytic Leukemia Research
Top Topic
Acute Myeloid Leukemia Research
Top Topic
Immune Cell Function and Interaction
Top Topic
470M+ articles · free account